AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04832438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 5 intravenously on Day 1 of a 21-day cycle
Study NCT06403774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group that will undergo bowel preparation using laxatives (Two bowel X-M Solution 250 ml.)
Description: A laxatives (Two bowel X-M Solution 250 ml.) will be applied for bowel preparation before hemorrhoidectomy. The drug was given to the patient at 3 o'clock (p.m.)before the surgery by mixing it with 1500ml of water.
Study NCT06403774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group that will undergo bowel preparation using enema (Two bowel E.S. Enema )
Description: An enema (Two bowel E.S. Enema ) will be applied for bowel preparation before hemorrhoidectomy.The drug was administered to the patient at 00 o'clock (a.m.) and 06 o'clock (a.m.) before the surgery.
Study NCT06057558 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Probiotic throat spray
Description: Throat spray containing Lacticaseibacillus casei AMBR2
Study NCT06340204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride Liposome Injection
Description: Irinotecan Hydrochloride Liposome Injection is given weekly by 5 doses every 6 weeks (5/6 qw).
Study NCT06228326 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KB707
Description: Genetically modified herpes simplex type 1 virus
Study NCT06423599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Injectable Product
Description: Weight loss using Semaglutide
Study NCT06423599 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calorie-restricted diet
Description: Weight loss by calorie-restricted diet program followed by a weight loss maintenance follow-up program
Study NCT06606990 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT06606990 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06606990 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT06606990 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT06606990 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06606990 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pidnarulex
Description: Given IV
Study NCT06623006 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile health (mhealth)
Description: The intervention will include a text-based mhealth component, designed using a behaviour change framework (Behaviour Change Wheel). The development process will be further informed by a formative research exploring perspectives of both health service providers and users on use of text based mhealth for supporting self-management in people with type 2 diabetes.
Study NCT06693830 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Phased Variant Enrichment and Detection Sequencing (PhasED-seq)
Description: PhasED-seq designed to detect minimal residual disease (MRD) as indicated by the presence of circulating tumor DNA (ctDNA) evidenced by an aggregate signal of phased variants (PVs) in the plasma of patients diagnosed with large B-cell lymphoma (LBCL) following first-line therapy.
Study NCT06693830 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care Treatment
Description: Standard of Care Treatment for cycles 1-6
Study NCT06693830 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: De-escalated Treatment
Description: Standard of Care Treatment for cycles 1-4 and de-escalated treatment for cycles 5 and 6
Study NCT06228326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYTRUDA®)
Description: PD-1 immune checkpoint inhibitor
Study NCT06228326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: SOC chemotherapy
Study NCT05002816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Elotuzumab will be administered via intravenous infusion at an established dose of 10 mg/kg on days 1, 8, 15, 22 every 28 days for cycles 1 and 2, followed by 20mg/kg on day 1 of each cycle thereafter, cycles repeated every 28 days.
Study NCT05779527 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Parenting Programme
Description: Online Mindful Parenting Programme with group support sessions
Study NCT05789121 — intervention group
Intervention type: DEVICE
Intervention: walking 25 m in 4 different conditions
Description: The protocol consisted of walking 25 m in 4 different conditions in the following order:~Gait1, RAS-Slow, RAS-fast, Gait2.~* Gait 1 : preferred cadence without auditory stimulation~* RAS-Slow : Gait with low tempo rhythmic auditory stimulation by music (68.5 per minute).~* RAS-Fast : Gait with fast tempo (10% above each Gait1 cadence).~* Gait2 : preferred cadence without auditory stimulation
Study NCT06693752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfur Hexafluoride Lipid Type A Microspheres 25 mg Injection Powder for Suspension [LUMASON]
Description: Injection of Sulfur hexafluoride lipid-type A microspheres contrast agent will be performed via the existing peripheral intravenous line using the FDA-recommended dose of 0.03 mg/kg before performing the contrast-enhanced ultrasound. The weight-based dose of 0.03 mL per kg will be repeated one time during a single examination. Following each injection, an intravenous flush of 0.9% Sodium Chloride is injected.
Study NCT06687980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Pharmaceutical form: Solution for injection Route of administration: subcutaneous injection
Study NCT06687980 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Solution for injection Route of administration: subcutaneous injection
Study NCT05002816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin will be administered via IV infusion on day 1 of each 28 day cycle. There will be 3 dose levels for belantamab mafodotin, with the starting dose of 1.9 mg/kg IV at every 4 week interval. Up to 12 subjects will be treated at this dose level. If the initial dose is found to be too toxic, dose of belantamab mafodotin 1.9 mg/kg every 8 weeks will be tested, further dose reduction to 1.4mg/kg every 8 weeks will be administered. Following the dose evaluation, there will be a dose expansion cohort wtih 12 additional subjects. There is no dose escalation planned in this study.
Study NCT05520762 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: A strategy of first choice supraglottic airway
Description: See description in Arms section
Study NCT05520762 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: A strategy of first choice supraglottic airway
Description: See description in Arms section
Study NCT05520762 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: A strategy of first choice endotracheal intubation
Description: See description in Arms section
Study NCT05520762 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: A strategy of first choice endotracheal intubation
Description: See description in Arms section
Study NCT05849662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: PO or NG QD Days 1-28~For patients age \< 6 years: 0.032 mg/kg/day at max dose = 2mg/day~For patients age ≥ 6 years: 0.025 mg/kg/day at max dose = 2 mg/day
Study NCT06110234 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Episodic Specificity Induction
Description: Recalling complex scenes using the Episodic Specificity Induction
Study NCT06110234 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Associative Memory
Description: Recalling word/picture pairs
Study NCT05849662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: IV over 30 minutes Days 1-5~Age \< 1 year or weight \<10kg:~2.5 mg/kg/day~Age ≥ 1 year and weight ≥ 10kg:~75 mg/m2/day
Study NCT05849662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: IV over 30 minutes Days 6-10~30 mg/m2/day (1mg/kg if \<12 kg)
Study NCT05849662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: IV over 3 hours Days 6-10~2000 mg/m2/day (67mg/kg if \<12 kg)
Study NCT05999721 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: superficial parasternal intercostal plane block
Description: Injection of 60 mL of bupivacaine 0.25% and epinephrine 2.5 µg mL-1
Study NCT05999721 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Operating Room:~Anaesthesia will be induced using midazolam (0.1-0.15 mg kg-1), fentanyl (5-10 μg kg-1), and rocuronium (0.6-1.2 mg kg-1); then, after tracheal intubation, anaesthesia will be maintained using isoflurane at one MAC, along with continuous fentanyl (3-5 μg kg-1 h-1) and midazolam (20-50 μg kg-1 h-1). Additional boluses of fentanyl will be administered according to the anesthesiologist's discretion.~Cardiothoracic Intensive Care Unit:~Continuous fentanyl will be maintained until tracheal extubation. All patients will receive intravenous multimodal analgesic drugs around the clock, including paracetamol 3 g day-1 and dipyrone 3 g day-1. If pain persists, rescue doses of either intravenous tramadol or morphine will be administered.~Cardiothoracic ward:~The analgesic protocol includes around-the-clock intravenous paracetamol 3 g day-1 and dipyrone 3 g day-1. If pain continues, rescue doses of oral oxycodone will be administered.
Study NCT06698328 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transauricular Vagus Nerve Stimulation
Description: Mild non-invasive electrical stimulation to the vagus nerve using electrodes or stickers that adhere to the ear and the surrounding area.
Study NCT06327490 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICG-guided manual lymphatic drainage
Description: Participants will perform manual lymphatic drainage on their affected arm using ICG lymphography images of the lymphatic pathway in their affected arm as guidance once daily for 2 years post-surgery.
Study NCT06327490 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional manual lymphatic drainage
Description: Participants will perform manual lymphatic drainage on their affected arm using traditional technique once daily for 2 years post-surgery.
Study NCT06327490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: All participants will be injected with indocyanine green for lymphatic mapping of the affected upper extremity, however this mapping will only be used to guide manual lymphatic drainage for participants on the ICG-guided manual lymphatic drainage arm.
Study NCT05262673 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antigen-specific T cells CART/CTL and DCvac
Description: Antigen-specific T cells CAR-T/CTL and DCvac cells to treat B-ALL
Study NCT05704244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 999326
Description: 75 mL FE 999326 (3 x 10\^11 vp/mL) of sterile suspension instilled once every 3 months into the bladder via a urinary catheter
Study NCT06357078 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Art Therapy
Description: Caregivers in the art therapy group will be given art therapy practices, lasting approximately 45 minutes-1 hour, twice a week for 4 weeks. Visual and handicraft practices (painting work, collage work, mandala work, painting with felt, clay work, painting and storytelling) are done in art therapy activities that will last for 4 weeks, and it is aimed to develop personal and emotional awareness, reduce stress and increase general well-being.
Study NCT06651190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Caregiver Resource (PainCaRe)
Description: The purpose of the PainCaRe mobile health app is to support parents of young children with cancer (between the ages of 2-11 years) to manage their cancer-related pain at home. The app will ask caregivers to completed a brief 6-question pain assessment once daily and complete ad hoc assessments as needed. Based on the results of the pain assessment, real-time, evidence-based pain management suggestions, including will be provided to parents. The purpose of the pilot randomized controlled trial (RCT) is to evaluate the feasibility of implementing PainCaRe in a future RCT. Please find attached the study protocol for reference.
Study NCT05179408 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted-telerehabilitation
Description: Participant-chosen targets: 1) inspiratory muscle training + walking (to reduce dyspnea and improve physical activity/stept count; 2) resistance training (to reduce fatigue and improve role/social function; 3) mindfulness training (to reduce fear of cancer recurrence and anxiety)
Study NCT06698328 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Sham non-invasive electrical stimulation using electrodes or stickers that adhere to the ear and the surrounding area.
Study NCT05589181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Buprenorphine
Description: 32mg of BUP split as 16mg at 0 minutes and 16mg at 30-60 min as an induction dose
Study NCT05589181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Buprenorphine Dose
Description: 12mg of buprenorphine (BUP) split as 8mg at 0 minutes and 4mg at time 30-60 min as an induction dose
Study NCT05477680 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Navigation-guided surgery
Description: Surgeon removes brain lesions and assesses brain shift with neuronavigation
Study NCT06098885 — intervention group
Intervention type: OTHER
Intervention: extraction orthodontic treatment
Description: bilateral upper first premolar extraction orthodontic treatment with moderate anchorage.
Study NCT06691386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product A
Description: Use of Test Product A in controlled use and ad libitum use sessions
Study NCT06336993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: herbal compound
Description: patients were instructed to take the herbal compound twice a day for 3 weeks, 200 to 300ml each time, composition of herbal compound of BSTL was BaiShao 9g, ChuanNiuXi 15g, DanShen 15g, DiLong 9g, DuHuo 9g, DuZhong 15g, GouJi 15g, QinJiao 9g, SangJiSheng 15g, XiXianCao 9g, XuChangQin 9g and YanHuSuo 9g, and herbs were provided by the Traditional Chinese Medicine pharmacy of Tongde Hospital in Zhejiang Province.
Study NCT06336993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Celecoxib (Ouyi Pharmaceutical Co., LTD., H20203296) was used twice a day for 3 weeks, 200mg/ time, to treat NSLBP;
Study NCT04686435 — intervention group
Intervention type: OTHER
Intervention: Non-surgical treatment such as physiotherapy, exercise, corticosteroid injection, medication, acupuncture
Description: Treatment consisting of different non-surgical interventions as recommended by the orthopedic specialist and decided upon in shared decision making with the patient
Study NCT04686435 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Description: Surgery can consist of rotator cuff repair, Bankart repair, subacromial decompression, biceps tenodesis or tenotomy, acromioclavicular joint resection.
Study NCT06368076 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: High intensity interval training on a bike or pedaltrainer from the wheelchair.
Study NCT03249844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone + prednisolone
Description: The experimental intervention consists of 5 consecutive days Methylprednisolone at a daily single intravenous dose of 20 mg/kg body-weight (max 1 g/day) followed by a 4-week course of tapering Prednisolone given at a daily single oral dose in the morning:~* week 1 and 2, oral Prednisolone 1 mg/kg/day (max 40 mg/day), ,~* week 3 and 4, oral Prednisolone 0,5 mg/kg/day (max 20 mg/day),
Study NCT06089395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jiajian Guishen granules
Description: This study was a stratified district group randomized, double-blind, double simulation, positive control clinical trial with JJGS granules + coenzyme Q10 simulant in the test group and JJGS granules simulant + coenzyme Q10 in the control group
Study NCT06089395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: coenzyme Q10
Description: This study was a stratified district group randomized, double-blind, double simulation, positive control clinical trial with JJGS granules + coenzyme Q10 simulant in the test group and JJGS granules simulant + coenzyme Q10 in the control group
Study NCT06691386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product B
Description: Use of Test Product B in controlled use and ad libitum use sessions
Study NCT05264207 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nursing students' home-visit programme
Description: 12-week home-visit program conducted by nursing students. Participants will receive weekly 45-minute visits. The visits will aim to promote self-care behaviours and will focus on:~1. Self-care of chronic conditions and medication management~2. Healthy habits: physical activity and healthy eating~3. Access to social support resources~4. Patients' rights and autonomous decision-making~The visits program will follow the WHO recommendations for the implementation of health promotion activities. All topics will be assigned 3 visits. In the first visit, the students will assess the participants' information needs and preferences in relation to the topic addressed and will provide generic information about it. In the second visit, the students will present individually-tailored information and will use individually-adapted strategies to convey such information. In the third visit, the student will explore the impact of the two previous visits and reinforce self-care behaviours.
Study NCT05264207 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care from Public Andalusian Health Service
Description: Standard care offered by the Public Andalusian Health Service in its portfolio of services for older adults with multiple chronic conditions and complex health conditions. As part of these services, older adults with multiple chronic conditions receive generic, written information on healthy eating, adapted physical activity, abandonment of toxic habits, environmental safety and emotional management when they are first diagnosed with a chronic condition. The action plans or protocols established in the care processes aimed at older people with chronic multimnorbidity do not include periodic home visits.
Study NCT05264207 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard care from Public Andalusian Health Service
Description: Standard care offered by the Public Andalusian Health Service in its portfolio of services for older adults with multiple chronic conditions and complex health conditions. As part of these services, older adults with multiple chronic conditions receive generic, written information on healthy eating, adapted physical activity, abandonment of toxic habits, environmental safety and emotional management when they are first diagnosed with a chronic condition. The action plans or protocols established in the care processes aimed at older people with chronic multimnorbidity do not include periodic home visits.
Study NCT05179122 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical drain
Description: In this arm a surgical drain will be inserted prior to surgical wound closure
Study NCT04814628 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: scenario 1 : pre-oxygenation with a face mask held by the anaesthetist
Description: the face mask is held by the anaesthetist (reference technique) to obtain effective pre-oxygenation for Oxygen Reserve Index (ORI) which has reached a plateau value for more than 10 seconds. All the usual supplies and medicines are available and in the same place as usual.~The sequence is as follows:~1. Patient lying on the operating table, start of the stopwatch~2. Opening of the computerized anaesthesia file~3. Monitoring (ECG, non-invasive blood pressure, SaO2) of the patient~4. Preparation of the hypnotic (propofol or thiopental, as desired)~5. Preparation of curare (succinylcholine or rocuronium, as desired)~6. Pre-oxygenation of the patient with the face mask held by the participating anaesthetist~7. Waiting for an ORI which has reached a plateau value for more than 10 seconds~8. Conditions for general anaesthesia met for the participating anaesthetist~9. End of simulation, stopwatch stop
Study NCT04814628 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: scenario 2: one anaesthetist in charge, face mask held by the patient for pre-oxygenation
Description: one anaesthetist is in charge of the simulated patient (volunteer), face mask held by the volunteer for pre-oxygenation for ORI which has reached a plateau value for more than 10 seconds All the usual supplies and medicines are available and in the same place as usual.~The sequence is as follows:~1. Patient entering the operating room, patient lying on the operating table, start of the stopwatch~2. Opening of the computerized anaesthesia file~3. Monitoring (ECG, non-invasive blood pressure, SaO2) of the patient~4. Preparation of the hypnotic (propofol or thiopental, as desired)~5. Preparation of curare (succinylcholine or rocuronium, as desired)~6. Face mask held by the patient for pre-oxygenation~7. Waiting for an ORI which has reached a plateau value for more than 10 seconds~8. Conditions for general anaesthesia met for the participating anaesthetist~9. End of simulation, stopwatch stop